Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants
Overview
Authors
Affiliations
Context: Individualized management, incorporating papillary thyroid cancer (PTC) variant-specific risk, is conceivably a useful treatment strategy for PTC, which awaits comprehensive data demonstrating differential risks of PTC variants to support.
Objective: This study sought to establish the differential clinicopathological risk of major PTC variants: conventional PTC (CPTC), follicular-variant PTC (FVPTC), and tall-cell PTC (TCPTC).
Methods: This was a retrospective study of clinicopathological outcomes of 6282 PTC patients (4799 females and 1483 males) from 26 centers and The Cancer Genome Atlas in 14 countries with a median age of 44 years (interquartile range, 33-56 y) and median follow-up time of 37 months (interquartile range, 15-82 mo).
Results: The cohort consisted of 4702 (74.8%) patients with CPTC, 1126 (17.9%) with FVPTC, and 239 (3.8%) with TCPTC. The prevalence of high-risk parameters was significantly different among the three variants, including extrathyroidal invasion, lymph node metastasis, stages III/IV, disease recurrence, mortality, and the use (need) of radioiodine treatment (all P < .001), being highest in TCPTC, lowest in FVPTC, and intermediate in CPTC, following an order of TCPTC > CPTC ≫ FVPTC. Recurrence and mortality in TCPTC, CPTC, and FVPTC were 27.3 and 6.7%, 16.1 and 2.5%, and 9.1 and 0.6%, corresponding to events per 1000 person-years (95% confidence interval [CI]) of 92.47 (64.66-132.26) and 24.61 (12.31-49.21), 34.46 (30.71-38.66), and 5.87 (4.37-7.88), and 24.73 (18.34-33.35) and 1.68 (0.54-5.21), respectively. Mortality hazard ratios of CPTC and TCPTC over FVPTC were 3.44 (95% CI, 1.07-11.11) and 14.96 (95% CI, 3.93-56.89), respectively. Kaplan-Meier survival analyses showed the best prognosis in FVPTC, worst in TCPTC, and intermediate in CPTC in disease recurrence-free probability and disease-specific patient survival. This was particularly the case in patients at least 45 years old.
Conclusion: This large multicenter study demonstrates differential prognostic risks of the three major PTC variants and establishes a unique risk order of TCPTC > CPTC ≫ FVPTC, providing important clinical implications for specific variant-based management of PTC.
Yan C, Zheng C, Luo J, Wu X, Meng X, Lv C J Pathol Clin Res. 2025; 11(2):e70022.
PMID: 40001321 PMC: 11860273. DOI: 10.1002/2056-4538.70022.
Shafaeipour A, Shirkhoda M, Karami M, Moosaie F, Jalaeefar A, Motiee-Langroudi M Med J Islam Repub Iran. 2024; 38:99.
PMID: 39678773 PMC: 11644028. DOI: 10.47176/mjiri.38.99.
Khalil E, Issa A, Kamal R Thyroid Res. 2024; 17(1):26.
PMID: 39648214 PMC: 11626750. DOI: 10.1186/s13044-024-00212-9.
Monabbati S, Fu P, Asa S, Pathak T, Willis J, Shi Q Lab Invest. 2024; 104(12):102168.
PMID: 39505213 PMC: 11659025. DOI: 10.1016/j.labinv.2024.102168.
Jin X, Fu C, Qi J, Chen C Clin Exp Med. 2024; 24(1):127.
PMID: 38869635 PMC: 11176101. DOI: 10.1007/s10238-024-01387-z.